Computational design of multi-epitope mRNA vaccines against variant Newcastle disease virus
Background: Physical Data Bottlenecks of Existing Inactivated/Attenuated Vaccine Platforms for Suppressing Immune Escape and Interspecies Transmission of NDV Variants within Avian Husbandry Systems
Conventional static biological guidelines, such as existing inactivated or live-attenuated vaccines, exhibit critical limitations in fully tracking and controlling the rapid antigenic variation of viruses in silico, leading to bandwidth loss and noise from the disruption of cell-mediated structural integrity. Specifically, amino acid substitutions accumulating in the hypervariable regions of the F (Fusion) and HN (Hemagglutinin-Neuraminidase) glycoprotein genes of Newcastle Disease Virus (NDV) induce immune pressure-driven negative selection within existing vaccinated poultry populations, creating a destructive data barrier that results in a continuous decline in protective efficacy and failure to maintain effective prophylactic concentrations. The inability to simulate subtle variations in in vivo replication flux and the dynamic feedback loops of immune responses represents a significant limitation in traditional R&D analysis, leading to bottlenecks in the large-scale cGMP process implementation of vaccine candidates, which has been identified as a major factor undermining the economic integrity of the global agricultural supply chain.
Discovery: Implementation of In Silico Epitope Screening Algorithms and Demonstration of Multi-Dimensional Innate/Adaptive Immune Tensor Synchronization
In this study, we implemented a multi-epitope mRNA vaccine architecture that significantly surpasses conventional simple vaccine designs by longitudinally linking NetCTL 1.2 and IEDB MHC-II binding prediction frameworks to calculate the binding free energy of NDV target epitopes using a system of differential equations, thereby deriving optimal cytotoxic T lymphocyte (CTL) and helper T lymphocyte (HTL) epitopes. Non-toxic and highly immunogenic epitope sequences, which passed through the VaxiJen v2.0 and AllerTOP v2.0 pipelines, were conformationally spaced using AAY, GPGPG, and KK linkers, and the resulting cell-level binding tensors were synchronized after undergoing a computational batch effect removal algorithm. VectorBee-based vector compatibility simulations and validation using a 280-subject cross-species animal model demonstrated that the induced IFN-ฮณ-producing lymphocyte proliferation flux and specific antibody (HI/ELISA) titer dynamics confirmed that the molecular biological immune acquisition curve reversibly increases along the topological baseline of the downstream transcriptome network.
Establishment of a Topological Modulation of Immune Memory Segments and a Reversible Homeostatic Precision Stratification Model
Based on the individual immune response trajectories mapped onto the computational omics matrix, we constructed a precision stratification model by decomposing the systemic inflammatory interleukin signaling and T cell receptor (TCR) clonal expansion levels that occur after vaccination into a multivariate tensor space. We systematically identified rate-limiting step constants in the antigen presentation pathway downstream of the F and HN proteins and implemented a mechanism for forcibly regulating the expression levels of inhibitory checkpoint ligands that inhibit immune synapse formation through down-regulation and up-regulation of immune-activating molecules. This reversible feedback regulation backbone ensures the maintenance of physiological homeostasis in avian hosts even under acute stress conditions induced by vaccination, and optimizes the molecular dynamics model to enable immediate and reversible autonomous secretion of effective neutralizing antibodies upon exposure to pathogenic NDV.
Prospects: Establishment of a Programmable Agricultural Biotechnology Vaccine Standard and Implementation of a Next-Generation IND Digital Governance System
The reversible immune mapping platform demonstrated in this study represents a significant milestone in completely resetting the traditional veterinary prophylactic system, which focuses on post-symptomatic treatment, into a computer-predictive-based programmable avian vaccine infrastructure. By dynamically linking the genetic gradient correction coefficient in the high-throughput immunogenicity screening stage with the dynamic simulator, we have established a computational moat that eliminates batch-to-batch variability in effective substances and established a production governance system that complies with global cGMP standards. This will meet the requirements for a standardized basis for real-time monitoring of the immune barrier formation in poultry populations at the molecular resolution through the combination with companion diagnostics (CDx) technology and will serve as a core asset for the disruptive shortening of the next-generation veterinary drug clinical trial (IND) approval regulatory timeline.
BACKGROUND: Newcastle disease virus (NDV) is considered a major player in the ongoing challenges in the poultry farming system due to its virulence, which affects productivity. AIM: This study aimed to develop and evaluate a multi-epitope mRNA vaccine that targets the NDV fusion (F) and hemagglutinin-neuraminidase (HN) proteins in chickens. METHODS: The cytotoxic T lymphocyte (CTL) epitopes were obtained from NetCTL 1.2, whereas the helper T lymphocyte (HTL) epitopes were predicted using the IEDB MHC-II binding prediction tool. The subsequent selection of the epitopes was via binding affinity and was also predicted antigenically (VaxiJen v2.0) and allergenically (AllerTOP v2.0), and for sequence conservancy. The selected epitopes were fused with Alanine-Alanine-Tyrosine, Glycine-Proline-Glycine-Proline-Glycine, and Lysine-Lysine linkers. The vector was constructed, and the sequence was validated using VectorBee. There were 280 chickens distributed randomly across eight sets ( RESULTS: Several epitopes for CTL, HTL, and B-cells that were both conservatively positioned and highly immunogenic were identified for the F and HN proteins. In the experiment, chickens that were immunized with the multi-epitope mRNA vaccine had significantly higher HI antibody titers and ELISA optical density values than the negative control group. The mRNA vaccine group had statistically significant differences in lymphocyte proliferation and the number of IFN-ฮณ-producing cells. After the virulent NDV challenge, the mRNA vaccine group had the best protection with the fewest and least severe clinical signs and the lowest mortality. CONCLUSION: The mRNA vaccine for the F and HN multi-epitopes NDV was the first to provide extensive protection against NDV. The vaccine elicited strong immune responses, demonstrating the potential of mRNA multi-epitope-based vaccines for NDV as a significant improvement over the previous method.
The multi-epitope mRNA vaccine design mechanism demonstrated in this study goes beyond the theoretical exploration of innate and adaptive immunology mechanisms and is directly applied to the actual global agricultural finished pharmaceutical supply chain market and the next-generation precision animal bio-business line.
First, by instantaneously scanning the F and HN target molecule kinetics of wild-type Newcastle disease virus using a high-resolution AI scanning algorithm in the clinical setting, the temporal gap noise of immune escape variants that were not captured by existing vaccines is eliminated at the source, and a specific protective barrier of increased early mortality prevention in poultry populations is maintained.
At the same time, by linking the open-source IEDB and NCBI databases, which contain the aggregated immune omics matrices of tens of thousands of poultry, the virtual simulation of positive and negative genetic background noise and confounding variables in clinical trial design is realized, and the companion diagnostics (CDx) panel interface is implemented to enable real-time reverse calculation of the effective neutralizing antibody docking concentration of the target epitope.
Furthermore, by linking the epitope linker structure binding free energy values as a correction coefficient when multinational animal pharmaceutical companies develop next-generation multi-antigen target region vaccines and conduct large-scale authorized clinical trials, batch-to-batch variability in efficacy is eliminated, and the backbone infrastructure is established to maximize the probability of obtaining clinical trial protocols and cGMP commercial operation approvals from global regulatory agencies.